Pub Date : 2020-02-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.02.017
S. Fan
Rectal cancer is one of the most common malignant tumors in China, and the proportion of elderly patients is also increasing. Due to the lack of prospective evidence-based medical research for elderly patients, no consensus on the optimal treatment model has been reached. In this article, relevant researches on the comprehensive treatment strategy of locally advanced rectal cancer in the elderly patients were reviewed, aiming to provide reference for individualized treatment of elderly patients. Key words: Rectal neoplasm/radiotherapy; Rectal neoplasm/chemotherapy; Rectal neoplasm/surgery; Elderly patient
{"title":"Research progress on treatment strategy for elderly patients with locally advanced rectal cancer","authors":"S. Fan","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.02.017","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.02.017","url":null,"abstract":"Rectal cancer is one of the most common malignant tumors in China, and the proportion of elderly patients is also increasing. Due to the lack of prospective evidence-based medical research for elderly patients, no consensus on the optimal treatment model has been reached. In this article, relevant researches on the comprehensive treatment strategy of locally advanced rectal cancer in the elderly patients were reviewed, aiming to provide reference for individualized treatment of elderly patients. \u0000 \u0000 \u0000Key words: \u0000Rectal neoplasm/radiotherapy; Rectal neoplasm/chemotherapy; Rectal neoplasm/surgery; Elderly patient","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"154-157"},"PeriodicalIF":0.0,"publicationDate":"2020-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45980520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.005
Ruilin Xie, Na Li, Qing-Feng Qin, Shengzi Wang, Xue Zhao, Zhaohui S. Qin, Yuanhu Yao
Objective To systematically evaluate the efficacy and safety between neoadjuvant concurrent chemoradiotherapy followed by surgery and surgery alone in the treatment of resectable esophageal squamous cell carcinoma. Methods Literature review was performed from Embase, PubMed, Web of Science, Cochrane Library, CBM, Wanfang Data, CNKI and Chongqing VIP. The randomized controlled clinical trials of concurrent chemoradiotherapy followed by surgery versus surgery alone in the treatment of resectable esophageal squamous cell carcinoma were retrieved. The meta-analysis of survival data, R0 resection rate, incidences of postoperative complications and peritreatment mortality was conducted by using RevMan 5.3 software. Results A total of 1450 patients from 11 controlled clinical trials were included in this meta-analysis. The results of the meta-analysis showed that concurrent chemoradiotherapy followed by surgery group had significantly higher 2-and 5-year overall survival rate (RR=1.14, 95%CI: 1.05-1.23, P=0.00) and progression-free survival rate (RR=1.56, 95%CI: 1.05-2.32, P=0.03). R0 resection rate were also improved in concurrent chemoradiotherapy followed by surgery group (RR=1.10, 95%CI: 1.05-1.14, P=0.00). Compared with the surgery alone group, the incidence of arrhythmia in the concurrent chemoradiotherapy plus surgery group was significantly higher (RR=2.45, 95%CI: 1.37-4.38, P=0.00). However, there was no significant difference in the overall incidence of postoperative complications (RR=1.12, 95%CI: 0.79-1.59, P=0.51) and incidence of peritreatment mortality (RR=1.78, 95%CI: 0.90-3.52, P=0.10) between two groups. Conclusions Neoadjuvant concurrent chemoradiotherapy followed by surgery improves the survival and R0 resection rate over surgery alone among patients with resectable esophageal squamous cell carcinoma, whereas it does not increase the risk of postoperative complications. Consequently, neoadjuvant concurrent chemoradiotherapy followed by surgery is an optimal treatment for patients with resectable esophageal squamous cell carcinoma. Key words: Esophageal neoplasm/neoadjuvant chemoradiotherapy; Esophageal neoplasm/surgery; Prognosis; Meta-analysis
目的系统评价新辅助放化疗联合手术治疗可切除食管鳞状细胞癌的疗效和安全性。方法查阅Embase、PubMed、Web of Science、Cochrane Library、CBM、万方数据、CNKI和重庆VIP的文献。检索了同时放化疗和手术治疗可切除食管鳞状细胞癌的随机对照临床试验。使用RevMan 5.3软件对生存数据、R0切除率、术后并发症发生率和治疗后死亡率进行荟萃分析。结果本荟萃分析共纳入了来自11项对照临床试验的1450名患者。荟萃分析结果显示，同时放化疗后手术组的2年和5年总生存率（RR=1.14，95%CI:1.05-1.23，P=0.00）和无进展生存率（RR=1.56，95%CI:1.05-2.32，P=0.03）显著较高。与单纯手术组相比，放化疗联合手术组心律失常的发生率显著高于单纯手术组（RR=2.45，95%CI:1.37-4.38，P=0.00），两组术后并发症的总发生率（RR=1.12，95%CI:0.79-1.59，P=0.51）和治疗后死亡率（RR=1.78，95%CI:0.90-3.52，P=0.10）无显著差异。结论在可切除的食管鳞状细胞癌患者中，新辅助放化疗联合手术比单独手术提高了生存率和R0切除率，但不会增加术后并发症的风险。因此，对于可切除的食管鳞状细胞癌患者，新辅助同期放化疗和手术是一种最佳的治疗方法。关键词：食管肿瘤/新辅助放化疗；食道肿瘤/外科手术；预后；Meta分析
{"title":"Efficacy and safety of neoadjuvant concurrent chemoradiotherapy followed by surgery versus surgery alone in the treatment of resectable esophageal squamous cell carcinoma: a Meta-analysis","authors":"Ruilin Xie, Na Li, Qing-Feng Qin, Shengzi Wang, Xue Zhao, Zhaohui S. Qin, Yuanhu Yao","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.005","url":null,"abstract":"Objective \u0000To systematically evaluate the efficacy and safety between neoadjuvant concurrent chemoradiotherapy followed by surgery and surgery alone in the treatment of resectable esophageal squamous cell carcinoma. \u0000 \u0000 \u0000Methods \u0000Literature review was performed from Embase, PubMed, Web of Science, Cochrane Library, CBM, Wanfang Data, CNKI and Chongqing VIP. The randomized controlled clinical trials of concurrent chemoradiotherapy followed by surgery versus surgery alone in the treatment of resectable esophageal squamous cell carcinoma were retrieved. The meta-analysis of survival data, R0 resection rate, incidences of postoperative complications and peritreatment mortality was conducted by using RevMan 5.3 software. \u0000 \u0000 \u0000Results \u0000A total of 1450 patients from 11 controlled clinical trials were included in this meta-analysis. The results of the meta-analysis showed that concurrent chemoradiotherapy followed by surgery group had significantly higher 2-and 5-year overall survival rate (RR=1.14, 95%CI: 1.05-1.23, P=0.00) and progression-free survival rate (RR=1.56, 95%CI: 1.05-2.32, P=0.03). R0 resection rate were also improved in concurrent chemoradiotherapy followed by surgery group (RR=1.10, 95%CI: 1.05-1.14, P=0.00). Compared with the surgery alone group, the incidence of arrhythmia in the concurrent chemoradiotherapy plus surgery group was significantly higher (RR=2.45, 95%CI: 1.37-4.38, P=0.00). However, there was no significant difference in the overall incidence of postoperative complications (RR=1.12, 95%CI: 0.79-1.59, P=0.51) and incidence of peritreatment mortality (RR=1.78, 95%CI: 0.90-3.52, P=0.10) between two groups. \u0000 \u0000 \u0000Conclusions \u0000Neoadjuvant concurrent chemoradiotherapy followed by surgery improves the survival and R0 resection rate over surgery alone among patients with resectable esophageal squamous cell carcinoma, whereas it does not increase the risk of postoperative complications. Consequently, neoadjuvant concurrent chemoradiotherapy followed by surgery is an optimal treatment for patients with resectable esophageal squamous cell carcinoma. \u0000 \u0000 \u0000Key words: \u0000Esophageal neoplasm/neoadjuvant chemoradiotherapy; Esophageal neoplasm/surgery; Prognosis; Meta-analysis","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"22-25"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43860607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.009
Dingjie Li, Ru Liu, Chengliang Yang, Jinhu Chen, Tai An, H. Ge
Objective To compare relevant dosimetric parameters of non-coplanar volumetric modulated arc therapy (VMAT) in treating brain tumors in conventional flattening filter (FF) or flattening filter-free (FFF) delivery mode, aiming to explore the appropriate evaluation method of accelerator for stereotactic radiosurgery (SRS). Methods Clinical data of 10 patients with single cranial tumor were retrospectively analyzed. All patients received non-coplanar VMAT at a prescription dose of 25 Gy in 1 fraction. Dosimetric parameters including conformity index (CI), heterogeneity index (HI), gradient index (GI50, GI25), gradient, volume of the brain tissue receiving larger than 10 Gy and 12 Gy(V10 and V12) and beam-on time were statistically compared between two treatment plans by paired sample t-test. Results When FFF-VMAT was compared with FF-VMAT in SRS for intracranial tumors, Paddick gradient index GI50 was 2.91±0.34 vs.3.07±0.35, 6.91±0.28 vs.7.35±0.27 for GI25, (0.57±0.07) cm vs.(0.61±0.08) cm for gradient, respectively (all P 0.05). For the normal brain tissues, the average dose was (160.64±43.64) cGy vs.(174.27±53.98) cGy, (45.35±30.32)% vs.(48.37±30.88)% for V10 and (36.69±25.15)% vs.(39.48±25.37)% for V12, respectively (all P<0.05). Conclusions Non-coplanar VMAT in FFF delivery mode can improve dose distribution and normal brain tissue sparing in the treatment of intracranial single tumors. Meanwhile, supplement of GI index and gradient index can implement comprehensive evaluation of the SRS planning. Key words: Brain neoplasm/stereotactic radiosurgery; Flattening filter-free beam; Dosimetry
{"title":"Dosimetric comparison between non-coplanar volumetric modulated arc therapy using flattening filter and flattening filter-free beams during stereotactic radiosurgery for brain tumors","authors":"Dingjie Li, Ru Liu, Chengliang Yang, Jinhu Chen, Tai An, H. Ge","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.009","url":null,"abstract":"Objective \u0000To compare relevant dosimetric parameters of non-coplanar volumetric modulated arc therapy (VMAT) in treating brain tumors in conventional flattening filter (FF) or flattening filter-free (FFF) delivery mode, aiming to explore the appropriate evaluation method of accelerator for stereotactic radiosurgery (SRS). \u0000 \u0000 \u0000Methods \u0000Clinical data of 10 patients with single cranial tumor were retrospectively analyzed. All patients received non-coplanar VMAT at a prescription dose of 25 Gy in 1 fraction. Dosimetric parameters including conformity index (CI), heterogeneity index (HI), gradient index (GI50, GI25), gradient, volume of the brain tissue receiving larger than 10 Gy and 12 Gy(V10 and V12) and beam-on time were statistically compared between two treatment plans by paired sample t-test. \u0000 \u0000 \u0000Results \u0000When FFF-VMAT was compared with FF-VMAT in SRS for intracranial tumors, Paddick gradient index GI50 was 2.91±0.34 vs.3.07±0.35, 6.91±0.28 vs.7.35±0.27 for GI25, (0.57±0.07) cm vs.(0.61±0.08) cm for gradient, respectively (all P 0.05). For the normal brain tissues, the average dose was (160.64±43.64) cGy vs.(174.27±53.98) cGy, (45.35±30.32)% vs.(48.37±30.88)% for V10 and (36.69±25.15)% vs.(39.48±25.37)% for V12, respectively (all P<0.05). \u0000 \u0000 \u0000Conclusions \u0000Non-coplanar VMAT in FFF delivery mode can improve dose distribution and normal brain tissue sparing in the treatment of intracranial single tumors. Meanwhile, supplement of GI index and gradient index can implement comprehensive evaluation of the SRS planning. \u0000 \u0000 \u0000Key words: \u0000Brain neoplasm/stereotactic radiosurgery; Flattening filter-free beam; Dosimetry","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"39-42"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42823769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.014
Xin Sun, Y. Men, Z. Hui
ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy, radiotherapy, target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities. Key words: Carcinoma, non-small cell lung/neoadjuvant therapy; Research progress
{"title":"Research progress onneoadjuvant therapy in stage IIIA-N2 non-small cell lung cancer","authors":"Xin Sun, Y. Men, Z. Hui","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.014","url":null,"abstract":"ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy, radiotherapy, target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small cell lung/neoadjuvant therapy; Research progress","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"61-64"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46125218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.008
Guanlin Lu, Shilin Fang, Yanan Peng, Qiu-ya Zhao, Xianyan Shi
Objective To preliminarily evaluate the clinical efficacy of endoscopic argon plasma coagulation (APC) combined with sub-mucosal injection of norepinephrine saline in the treatment of radiation proctitis (RP), especially for refractory RP. Methods Clinical data of 22 RP patients were retrospectively analyzed. The severity of RP was evaluated by a modified endoscopy scoring system (A) or Sherman′s classification (B). The criteria of successful treatment are the improvement of clinical symptoms or the cessation of bleeding (or only occasional traces of blood on the stools that do not need further treatment). Results All 22 patients were successfully treated. Among them, 18 patients (82%) had no bleeding. According to the classification of A, 15 patients (68%) had mild proctitis and 7(32%) experienced severe proctitis. Based on B classification, 9 patients (41%) were categorized as mild proctitis and 13(59%) as severe proctitis. Using the classification of A, the number of treatment sessions was significantly correlated with the endoscopic grade (or endoscopic total score)(Spearman’s r=0.86, P<0.001). Conclusions Preliminary evidence demonstrates that endoscopic APC combined with sub-mucosal injection of norepinephrine saline is not only effective for mild and moderate RP, but also maintains long-term efficacy for refractory RP. Modified endoscopy scoring system (A) assessment is more suitable for clinical application compared with B assessment. Key words: Radiation proctitis/argon plasma coagulation; Radiation proctitis/combined therapy; Treatment outcome
{"title":"Preliminary clinical analysis of radiation proctitis treated with argon plasma coagulation combined with submucosal injection","authors":"Guanlin Lu, Shilin Fang, Yanan Peng, Qiu-ya Zhao, Xianyan Shi","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.008","url":null,"abstract":"Objective \u0000To preliminarily evaluate the clinical efficacy of endoscopic argon plasma coagulation (APC) combined with sub-mucosal injection of norepinephrine saline in the treatment of radiation proctitis (RP), especially for refractory RP. \u0000 \u0000 \u0000Methods \u0000Clinical data of 22 RP patients were retrospectively analyzed. The severity of RP was evaluated by a modified endoscopy scoring system (A) or Sherman′s classification (B). The criteria of successful treatment are the improvement of clinical symptoms or the cessation of bleeding (or only occasional traces of blood on the stools that do not need further treatment). \u0000 \u0000 \u0000Results \u0000All 22 patients were successfully treated. Among them, 18 patients (82%) had no bleeding. According to the classification of A, 15 patients (68%) had mild proctitis and 7(32%) experienced severe proctitis. Based on B classification, 9 patients (41%) were categorized as mild proctitis and 13(59%) as severe proctitis. Using the classification of A, the number of treatment sessions was significantly correlated with the endoscopic grade (or endoscopic total score)(Spearman’s r=0.86, P<0.001). \u0000 \u0000 \u0000Conclusions \u0000Preliminary evidence demonstrates that endoscopic APC combined with sub-mucosal injection of norepinephrine saline is not only effective for mild and moderate RP, but also maintains long-term efficacy for refractory RP. Modified endoscopy scoring system (A) assessment is more suitable for clinical application compared with B assessment. \u0000 \u0000 \u0000Key words: \u0000Radiation proctitis/argon plasma coagulation; Radiation proctitis/combined therapy; Treatment outcome","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"35-38"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42551728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.1.012
Xueyuan Li, Qiankun Liu, Shanpeng Yuan, Y. Zhen, Lixin Wu, Wenzheng Luo, Kang Wang, Zhuang Wang, P. Gao, T. Liang, Dongming Yan
Objective To investigate the effect of lncRNA GIHCG on the radiosensitivity of glioma cells and its mechanism. Methods The expression levels of GIHCG and miR-146a-3p in human brain normal glial cells HEB and glioma cell lines U251, A172, SHG139 and U87 were quantitatively measured by qRT-PCR assay. U251 and SHG139 cells were used for subsequent experiment. After silencing the expression of GIHCG or overexpressing miR-146a-3p in U251 and SHG139 cells, cell proliferation was detected by MTT assay, cell apoptosis was detected by flow cytometry, cell radiosensitivity was detected by colony formation assay and the expression levels of CDK1, CyclinD1, Bcl-2 and Bax proteins were measured by Western blot. The bioinformatics software predicted the presence of a binding site for GIHCG and miR-146a-3p. Dual luciferase reporter gene assay and qRT-PCR assay were adopted to verify the targeting relationship between GIHCG and miR-146a-3p. Results Compared with HEB cells, the expression of GIHCG was significantly up-regulated in glioma U87, U251, A172 and SHG139 cells (all P<0.05), whereas that of miR-146a-3p was remarkably down-regulated (P<0.05). Silencing GIHCG expression or overexpression of miR-146a-3p significantly decreased the U251 and SHG139 cell survival rate, survival fraction and the expression of CDK1, CyclinD1 and Bcl-2 proteins (all P<0.05), whereas considerably increased the apoptotic rate and expression of Bax protein (both P<0.05). GIHCG performed targeted negative regulation of miR-146a-3p expression in U251 and SHG139 cells and inhibition of miR-146a-3p expression reversed the effect of silencing GIHCG on proliferation, apoptosis and radiosensitivity of glioma cells. Conclusion Silencing GIHCG expression up-regulates the expression of miR-146a-3p, thereby enhancing the radiosensitivity of glioma cells. Key words: Glioma; lncRNA GIHCG; miR-146a-3p gene; Radiosensitivity
{"title":"Silencing lncRNA GIHCG increases radiosensitivity of glioma cells by up-regulating miR-146a-3p","authors":"Xueyuan Li, Qiankun Liu, Shanpeng Yuan, Y. Zhen, Lixin Wu, Wenzheng Luo, Kang Wang, Zhuang Wang, P. Gao, T. Liang, Dongming Yan","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.1.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.1.012","url":null,"abstract":"Objective \u0000To investigate the effect of lncRNA GIHCG on the radiosensitivity of glioma cells and its mechanism. \u0000 \u0000 \u0000Methods \u0000The expression levels of GIHCG and miR-146a-3p in human brain normal glial cells HEB and glioma cell lines U251, A172, SHG139 and U87 were quantitatively measured by qRT-PCR assay. U251 and SHG139 cells were used for subsequent experiment. After silencing the expression of GIHCG or overexpressing miR-146a-3p in U251 and SHG139 cells, cell proliferation was detected by MTT assay, cell apoptosis was detected by flow cytometry, cell radiosensitivity was detected by colony formation assay and the expression levels of CDK1, CyclinD1, Bcl-2 and Bax proteins were measured by Western blot. The bioinformatics software predicted the presence of a binding site for GIHCG and miR-146a-3p. Dual luciferase reporter gene assay and qRT-PCR assay were adopted to verify the targeting relationship between GIHCG and miR-146a-3p. \u0000 \u0000 \u0000Results \u0000Compared with HEB cells, the expression of GIHCG was significantly up-regulated in glioma U87, U251, A172 and SHG139 cells (all P<0.05), whereas that of miR-146a-3p was remarkably down-regulated (P<0.05). Silencing GIHCG expression or overexpression of miR-146a-3p significantly decreased the U251 and SHG139 cell survival rate, survival fraction and the expression of CDK1, CyclinD1 and Bcl-2 proteins (all P<0.05), whereas considerably increased the apoptotic rate and expression of Bax protein (both P<0.05). GIHCG performed targeted negative regulation of miR-146a-3p expression in U251 and SHG139 cells and inhibition of miR-146a-3p expression reversed the effect of silencing GIHCG on proliferation, apoptosis and radiosensitivity of glioma cells. \u0000 \u0000 \u0000Conclusion \u0000Silencing GIHCG expression up-regulates the expression of miR-146a-3p, thereby enhancing the radiosensitivity of glioma cells. \u0000 \u0000 \u0000Key words: \u0000Glioma; lncRNA GIHCG; miR-146a-3p gene; Radiosensitivity","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"52-56"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48299882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.011
Yang He, Jinyan Lei, H. Peng, Huanli Luo, K. Mao, Dengyan Wang, Lifeng Peng, Yiyu Zhu, Qinghong Min, Xuechun Wang, Huan Tang, Qian Xiao, Ying Wang
Objective To investigate the correlation between skin elasticity and setup error in optical surface image-guided radiotherapy. Methods The skin elasticity (R7) data of the head, chest and abdomen were extracted and analyzed its correlation with age by systematic literature review. Fifty-four patients diagnosed with nasopharyngeal carcinoma, breast cancer and cervical cancer were recruited in this study. Firstly, the patients were positioned based on the room laser and markers. Subsequently, the patient position was verified by the Varian On-Board Imager, and then C-Rad Catalyst was adopted to obtain surface images in two states (mask or non-mask) as reference images. In the subsequent fraction treatment, after initial positioning, the local calibration was performed by Catalyst, and setup errors in three directions were recorded. Meanwhile, the patient setup was verified by CBCT twice a week. The Pearson correlation analysis was performed to analyze the correlation between setup error and age. Results The skin elasticity was negatively correlated with aging (P SI>AP. Conclusion In optical surface-guided radiotherapy of head and neck cancer, skin elasticity may be a significant index for assessing the setup errors in male patients. Key words: Skin elasticity; Surface image-guided radiotherapy; Set-up error
{"title":"The effect of age on skin elasticity and setup error in optical surface image-guided radiotherapy","authors":"Yang He, Jinyan Lei, H. Peng, Huanli Luo, K. Mao, Dengyan Wang, Lifeng Peng, Yiyu Zhu, Qinghong Min, Xuechun Wang, Huan Tang, Qian Xiao, Ying Wang","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.011","url":null,"abstract":"Objective \u0000To investigate the correlation between skin elasticity and setup error in optical surface image-guided radiotherapy. \u0000 \u0000 \u0000Methods \u0000The skin elasticity (R7) data of the head, chest and abdomen were extracted and analyzed its correlation with age by systematic literature review. Fifty-four patients diagnosed with nasopharyngeal carcinoma, breast cancer and cervical cancer were recruited in this study. Firstly, the patients were positioned based on the room laser and markers. Subsequently, the patient position was verified by the Varian On-Board Imager, and then C-Rad Catalyst was adopted to obtain surface images in two states (mask or non-mask) as reference images. In the subsequent fraction treatment, after initial positioning, the local calibration was performed by Catalyst, and setup errors in three directions were recorded. Meanwhile, the patient setup was verified by CBCT twice a week. The Pearson correlation analysis was performed to analyze the correlation between setup error and age. \u0000 \u0000 \u0000Results \u0000The skin elasticity was negatively correlated with aging (P SI>AP. \u0000 \u0000 \u0000Conclusion \u0000In optical surface-guided radiotherapy of head and neck cancer, skin elasticity may be a significant index for assessing the setup errors in male patients. \u0000 \u0000 \u0000Key words: \u0000Skin elasticity; Surface image-guided radiotherapy; Set-up error","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"47-51"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48924403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.004
W. Shen, Hong-mei Gao, Shuchai Zhu, Y. Cao, Shu-guang Li, Jinrui Xu
Objective To evaluate the effect of different irradiation methods on the long-term prognosis of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, aiming to select the optimal treatment for these patients. Methods A total of 268 eligible patients admitted to our hospital from January 2007 to December 2012 were enrolled in this study. All patients were divided into the involved-field irradiation (IFI) and elective node irradiation (ENI) groups. The composition ratio, prognostic factors and adverse events were analyzed between two groups. Results The median overall survival (OS) time was 35.5 months (95%CI : 30.12-40.88) and the median disease-free survival (DFS) time was 23.5 months (95%CI: 19.00-28.00). According to the multivariate analysis results, all patients were assigned into two groups at a ratio of 1 vs.1(n=86 in each group). Multivariate analysis after propensity score matching (PSM) demonstrated that irradiation method was the independent factor of OS (P=0.038), and T stage and radiotherapy were the independent factors affecting DFS (P=0.002, 0.032). The incidence of ≥grade Ⅱ adverse events did not significantly differ between two groups (P=0.819, 0.756). However, patients with combined chemotherapy experienced more adverse events. Conclusion ENI can prolong the OS and DFS of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, and does not increase the incidence of severe adverse events. Key words: Esophageal neoplasm/involved-field irradiation; Esophageal neoplasm/elective node irradiation; Prognosis
{"title":"Prognosis of different irradiation methods in patients with T2-3N0M0 esophageal squamous cell carcinoma","authors":"W. Shen, Hong-mei Gao, Shuchai Zhu, Y. Cao, Shu-guang Li, Jinrui Xu","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.004","url":null,"abstract":"Objective \u0000To evaluate the effect of different irradiation methods on the long-term prognosis of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, aiming to select the optimal treatment for these patients. \u0000 \u0000 \u0000Methods \u0000A total of 268 eligible patients admitted to our hospital from January 2007 to December 2012 were enrolled in this study. All patients were divided into the involved-field irradiation (IFI) and elective node irradiation (ENI) groups. The composition ratio, prognostic factors and adverse events were analyzed between two groups. \u0000 \u0000 \u0000Results \u0000The median overall survival (OS) time was 35.5 months (95%CI : 30.12-40.88) and the median disease-free survival (DFS) time was 23.5 months (95%CI: 19.00-28.00). According to the multivariate analysis results, all patients were assigned into two groups at a ratio of 1 vs.1(n=86 in each group). Multivariate analysis after propensity score matching (PSM) demonstrated that irradiation method was the independent factor of OS (P=0.038), and T stage and radiotherapy were the independent factors affecting DFS (P=0.002, 0.032). The incidence of ≥grade Ⅱ adverse events did not significantly differ between two groups (P=0.819, 0.756). However, patients with combined chemotherapy experienced more adverse events. \u0000 \u0000 \u0000Conclusion \u0000ENI can prolong the OS and DFS of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, and does not increase the incidence of severe adverse events. \u0000 \u0000 \u0000Key words: \u0000Esophageal neoplasm/involved-field irradiation; Esophageal neoplasm/elective node irradiation; Prognosis","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"17-21"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42050012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.016
Liqing Zou, Yida Li, Xi Yang
Hyperthermia has been a research hot spot since it was approved by FDA as one of the 5 major therapeutic modalities for tumor since 1989. Pre-clinicaland clinical researches have confirmed the prominent radiosensitizing effect of hyperthermia. In this article, the research progress on hyperthermia combined with radiation therapy was summarized based upon clinical evidence. The challenges and issues during the procedure of hyperthermia combined with radiation therapy were analyzed from the perspectives of treatment temperature, frequency and interval time of hyperthermia, interval time and time sequence between hyperthermia and radiation therapy, etc. Besides, the application progress and prospect of hyperthermia combined with radiation therapy were reviewed, aiming to provide clinical evidence for the combination of hyperthermia and radiation therapy. Key words: Neoplasm/radiotherapy; Neoplasm/hyperthermia; Neoplasm/hyperthermia combined with radiation therapy; Research progress
{"title":"Progress on clinical research of hyperthermia combined with radiation therapy","authors":"Liqing Zou, Yida Li, Xi Yang","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.016","url":null,"abstract":"Hyperthermia has been a research hot spot since it was approved by FDA as one of the 5 major therapeutic modalities for tumor since 1989. Pre-clinicaland clinical researches have confirmed the prominent radiosensitizing effect of hyperthermia. In this article, the research progress on hyperthermia combined with radiation therapy was summarized based upon clinical evidence. The challenges and issues during the procedure of hyperthermia combined with radiation therapy were analyzed from the perspectives of treatment temperature, frequency and interval time of hyperthermia, interval time and time sequence between hyperthermia and radiation therapy, etc. Besides, the application progress and prospect of hyperthermia combined with radiation therapy were reviewed, aiming to provide clinical evidence for the combination of hyperthermia and radiation therapy. \u0000 \u0000 \u0000Key words: \u0000Neoplasm/radiotherapy; Neoplasm/hyperthermia; Neoplasm/hyperthermia combined with radiation therapy; Research progress","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"69-72"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46947586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.015
Xiangbin Zhang, Guangjun Li, Ying-jie Zhang
Dose-guided radiotherapy (DGRT) is a potentially useful adaptive radiotherapy method which dosimetrically compensates for interfractional non-rigid deformation. With the improvement of in-room imaging quality, development of the deformation registration algorithm and innovation of computer science, the wide application of DGRT might be realized. The purpose of this article is to briefly summarize the work flow, clinical application and prospect of DGRT. Key words: Dose-guided radiotherapy; Interfractional non-rigid deformation; Adaptive radiotherapy
{"title":"Clinical application and research progress on dose-guided radiotherapy","authors":"Xiangbin Zhang, Guangjun Li, Ying-jie Zhang","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.015","url":null,"abstract":"Dose-guided radiotherapy (DGRT) is a potentially useful adaptive radiotherapy method which dosimetrically compensates for interfractional non-rigid deformation. With the improvement of in-room imaging quality, development of the deformation registration algorithm and innovation of computer science, the wide application of DGRT might be realized. The purpose of this article is to briefly summarize the work flow, clinical application and prospect of DGRT. \u0000 \u0000 \u0000Key words: \u0000Dose-guided radiotherapy; Interfractional non-rigid deformation; Adaptive radiotherapy","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"65-68"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45463451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：